Fish oil (medical use)

Fish oil
Clinical data
Trade namesOmegaven
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Dependence
liability		Intravenous
Drug classIntravenous nutritional products
ATC code
  • None
Legal status
Legal status

Fish oil, sold under the brand name Omegaven, is a fatty acid emulsion.[2] It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome.[2] It is rich in omega-3 fatty acids.[2]

Fish oil is made up of 2 Omega-3 fatty acids, Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA).

It has gained popularity in children in preference to the more commonly used Intralipid after case reports that it reduced the risk of liver damage.[3]

A 2007 study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastroschisis, and intestinal atresia.[4]

A clinical trial exploring the use of fish oil as an adjunct to parenteral nutrition in surgical intensive care units at National Taiwan University Hospital completed in March 2007.[5]

Although the use of fish oil triglycerides in children in the United States is experimental, the use of it in adults in Europe is less controversial.[6] In European studies, fish oil triglycerides have been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven.[7] Fish oil triglycerides have also been associated with reduced mortality and antibiotic use during hospital stays.[8]

Fish oil triglycerides was approved for use in the United States on July 27, 2018,[9] and is available to patients on the US market by prescription effective November 15, 2018.[10]

References

  1. ↑ "Fat emulsion Use During Pregnancy". Drugs.com. 4 May 2020. Retrieved 12 May 2020.
  2. 1 2 3 4 "Omegaven- fish oil injection, emulsion". DailyMed. 6 August 2018. Retrieved 13 May 2020.
  3. ↑ Gura KM, Duggan CP, Collier SB, et al. (2006). "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management". Pediatrics. 118 (1): e197–201. doi:10.1542/peds.2005-2662. PMID 16818533. S2CID 46567040.
  4. ↑ Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK (2007). "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease". Journal of Perinatology. 27 (5): 284–90. doi:10.1038/sj.jp.7211686. PMID 17344923.
  5. ↑ Clinical trial number NCT00172198 for "Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU." at ClinicalTrials.gov
  6. ↑ A Doctor's Push For Drug Pits Him Against Its Maker at The Wall Street Journal
  7. ↑ Mayser P, Grimm H, Grimminger F (2002). "n-3 fatty acids in psoriasis". Br. J. Nutr. 87. Suppl 1: S77–82. doi:10.1079/bjn2001459. PMID 11895157.
  8. ↑ Heller AR, Rössler S, Litz RJ, et al. (2006). "Omega-3 fatty acids improve the diagnosis-related clinical outcome". Crit. Care Med. 34 (4): 972–9. doi:10.1097/01.CCM.0000206309.83570.45. PMID 16484909. S2CID 32537029.
  9. ↑ "Drug Approval Package: Omegaven (fish oil triglycerides)". U.S. Food and Drug Administration (FDA). 24 August 2018. Retrieved 12 May 2020.
  10. ↑ Research, Center for Drug Evaluation and. "Investigational New Drug (IND) Application - How to request Omegaven for Expanded Access Use". www.fda.gov. Retrieved 2019-02-15.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.